This editorial refers to 'Mechanical aortic valve replacement in non-elderly adults: meta-analysis and microsimulation' † , by N.M. Korteland et al., on page 3370.
Aortic stenosis is the most common form of valvular heart disease in the developed world, and valve replacement is still the standard treatment. Mechanical valves are generally preferred over tissue valves for younger patients with aortic stenosis because of their greater durability. Information provided on The American Heart Association website suggests that most manufactured mechanical valves 'will last throughout the remainder of the patients' lifetime', 1 but the life expectancy of younger patients with aortic stenosis is almost halved at the time of valve implantation. 2 In this issue of the journal, Takkenberg and colleagues explore outcomes after bi-leaflet mechanical aortic valve replacement in younger patients by performing a meta-analysis of 29 observational studies published between 1995 and 2015 that involved 5728 patients aged 18-55 years (mean age 48 years). 3 Their pooled results indicate early (<30 days) mortality of 3.15% and late (>30 days) mortality of 1.55%/ year (of which 38.7% were valve related); and annual rates of thrombo-embolism of 0.90%, major bleeding of 0.85%, nonstructural valve dysfunction of 0.39%, endocarditis of 0.41%, valve thrombosis of 0.14%, and re-intervention of 0.51%. The pooled mean follow-up was only 5.7 years, but using a microsimulation model they estimated age-specific life expectancy and lifetime risk of valverelated morbidity. For example, they estimated that a 45-year-old undergoing mechanical valve replacement has a life expectancy of 19 years (compared with 34 years in the general population), and lifetime risk of thrombo-embolism, bleeding, and re-intervention of 18, 15, and 10%, respectively. The results of Takkenberg and colleagues need to be cautiously interpreted because they are based on observational studies with substantial potential for selection, reporting, and publication bias, and on simulations that require assumptions about event rates beyond the observed follow-up period. Despite these potential limitations, their results are consistent with individual published reports and most probably provide the most reliable estimates of event rates and survival for younger patients undergoing mechanical aortic valve replacement
What are the implications of these data for clinical practice?
The durability of mechanical valves shown by Takkenberg and colleague supports their preferential use in younger patient, but there is clearly an urgent need to improve anticoagulant therapy because of the very high lifetime rate of thrombo-embolic and bleeding complications. Potential approaches to improving anticoagulant therapy might include increasing the quality of international normalized ratio (INR) control, reducing the intensity of anticoagulation in patients implanted with less thrombogenic valves, or testing of alternative agents that are more effective and safer.
Randomized trials have demonstrated that the quality of vitamin K antagonist therapy can be optimized by self-monitoring and management by specialist clinics, but these approaches are resourceintensive, and even in the best of hands rarely achieve a time in therapeutic range >75%.
Reducing the intensity of warfarin anticoagulation in patients implanted with less thrombogenic valves has had limited success. The PROACT trial conducted in 375 patients with an On-X mechanical aortic valve replacement showed that on a background of aspirin, lower intensity (INR 1.5-2.0) compared with standard intensity (INR 2.0-3.0) warfarin reduced bleeding without compromising efficacy. Despite this promising result, the annual rate of any bleeding with lower intensity therapy was still 2.74%/year and the composite of bleeding, thrombo-embolism, and thrombosis was 4.57%/year; 4 these annual event rates remain a major concern for younger patients facing life-long anticoagulant therapy. Furthermore, targeting a lower INR range does not obviate the need for routine coagulation monitoring and lifestyle restrictions, and the teratogenicity of vitamin K antagonists is highly problematic for women of child-bearing age. Tecarfarin is a highly promising new vitamin K antagonist that is metabolized exclusively by carboxyl esterases, thereby eliminating some of the variability associated with the cytochrome-mediated metabolism of traditional vitamin K antagonists. By producing more stable anticoagulation, tecarfarin has the potential to reduce bleeding and thrombo-embolic complications, but this remains to be demonstrated in outcome studies. 5 The attraction of non-vitamin K antagonist oral anticoagulants (NOACs) is that they have been shown in other clinical settings to be at least as effective as warfarin with less bleeding, and are much more convenient because they do not require routine coagulation monitoring. However, in patients with mechanical heart valves, the oral direct thrombin inhibitor, dabigatran etexilate, was less effective than warfarin for prevention of thrombo-embolic complications and produced more bleeding. Apixaban and rivaroxaban, which target coagulation factor Xa, have shown promise in pre-clinical mechanical heart valve studies, 6 but human studies are yet to be performed.
Based on emerging evidence suggesting that thrombosis in patients with mechanical heart valves results from upstream activation of the contact pathway through factor XII, other experimental drugs currently under development that selectively target factor XI or factor XII may prove successful for this indication.
The most common alternative to a mechanical valve is a biological valve. Similar to mechanical valves, biological valve implantation is associated with reduced life expectancy in younger patients with advanced aortic valve disease. 2, 7, 8 Thus, a 40-year-old patient undergoing biological valve implantation today has a 20 year reduction in life expectancy, and, after 20 years, only 38% will be alive and without re-operation for valve deterioration.
The major attraction of a biological valve for patients is avoidance of the need for life-long anticoagulation. However, recent data suggest that subclinical biological valve thrombosis is much more 
common than previously thought, and is an important cause of adverse outcomes. 9 Thus four-dimensional computed tomographic imaging has detected small thrombi in 7-10% of patients with a biological aortic valve replacement. These thrombi are believed to be associated with increased risk of both transient ischaemic attack and early valve degeneration. NOACs appear to be effective for the treatment of biological valve thrombi and are currently being tested in the ATLANTIS trial and Envisage-TAVI AF trials in patients undergoing transcatheter aortic valve implantation. 10, 11 However, even if thrombo-embolism can be prevented by anticoagulation, biological valves cannot be expected to provide life expectancy similar to that of the general population. The landscape of bioprosthetic valve replacement is changing, as techniques for valve-in-valve transcatheter aortic valve implantation (TAVI) evolve. Small studies have shown promising short-term mortality outcomes when compared with conventional re-operation, but further investigation is required to determine long-term outcomes. 12 If the risk associated with structural valve dysfunction requiring reoperation is mitigated with low-risk re-intervention options, improvements in survival may be achieved.
The only other option for younger patients requiring aortic valve replacement is pulmonary autograft (the Ross procedure). With this approach, the patient's native pulmonary valve is autografted to the aortic position and a homograft bioprosthesis is implanted to the pulmonary position, where the lower pressures of the pulmonary circulation result in improved durability of the prosthesis.
The Ross procedure was developed with the aim of providing a durable aortic valve substitute with optimal haemodynamics while avoiding the need for lifelong anticoagulation. [13] [14] [15] The main disadvantages of the Ross procedure are its surgical complexity and the iatrogenic creation of pathology in the right ventricular outflow tract (RVOT) with associated risk of pulmonary homograft failure. 16, 17 Furthermore, TAVI has not been evaluated for re-intervention of the autografted valve. Unfavourable early results have further dampened enthusiasm for the Ross procedure, and very few surgeons have expertise in the technique. Nevertheless, some believe that failure to use the Ross procedure is a lost opportunity for younger patients with aortic valve disease. 18 In 2009, Takkenberg and colleagues published a systematic review and meta-analysis of 39 studies involving 1749 patients undergoing the Ross procedure. The results suggested favourable rates of late mortality (0.64%/year), structural and non-structural valve dysfunction [left ventricular outflow tract (LVOT) site 0.78%/year, RVOT site 0.55%/year], and the composite of thrombo-embolism, bleeding, and valve thrombosis (0.36%/year), but high early mortality (3.2%).
More recently, an analysis from the STS database involving 2188 patients with a mean age of 42 showed increased operative mortality with the Ross procedure when compared with conventional tissue aortic valve replacement [relative risk (RR) 3.0, 95% confidence interval (CI) 1.5-6.1, absolute risk 2.7%]. These results did not adjust for lack of surgical expertise at low volume Ross centres. 19 On the other hand, large propensity-matched cohort analyses have suggested longterm survival with the Ross procedure comparable with that of the general population and lower rates of re-operation than biological and mechanical valve prosthesis. [20] [21] [22] Similar results have been reported from a single-centre, single-surgeon randomized controlled trial comparing the Ross procedure with homograft surgery (n = 216). 13 However, most of the data on the Ross procedure are of low quality, and lack of surgical expertise limits the generalizability of the results. Current ESC/EACTS Guidelines suggest that the main advantage of the Ross procedure is in children. 23 Further evaluation of the Ross procedure for younger adults would ideally be performed using an expertise-based randomized controlled trial in which patients randomized to the Ross procedure are treated by surgeons with expertise in the surgical technique.
In 2017, the role of valve replacement as the only definitive treatment for advanced aortic valve disease remains unquestioned, but outcomes are suboptimal. The choice of prosthesis is complex and must take into account patient characteristics and preferences as well as surgical expertise (Figure 1) . There is, as of yet, no perfect replacement for the native aortic valve, and nowhere is this clearer than in younger adults. The work by Takkenberg and colleagues helps us to better appreciate the challenges and paves the way for intensified efforts to improve outcomes for these patients.
